Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGAVE-201 axatilimab dose-ranging study in chronic graft-versus-host disease
MOH_2021-11-25_010408Phase 2Active, not recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of axatilimab in chronic graft-versus-host disease (cGVHD) (3 arms), sponsored by Syndax Pharmaceuticals. Started Nov 2021; status: active, not recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on MOH_2021-11-25_010408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-25_010408.